Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

RCT (n=19) reports linagliptin as add-on treatment to glimepiride did not improve primary end point of mean amplitude of glycaemic excursions (mean difference −0.7 mmol/L, P = 0.1540), but did improve glycaemic variability and control without increasing risk of hypoglycaemia.

SPS commentary:

In terms of secondary outcome measures, compared with glimepiride plus placebo, glimepiride plus linagliptin displayed statistically significant reductions in coefficient of variation on continuous glucose monitoring (−3.6%, P = 0.0401), HbA1c (−0.5%, P = 0.0048), and glimepiride dose (−0.7 mg/day, P = 0.0099).


Diabetes Care